C-Peptide's Role in Diabetic Neuropathy for Type 1 Diabetes
Author Information
Author(s): Karin Ekberg, Bo-Lennart Johansson
Primary Institution: Karolinska Institute
Hypothesis
C-peptide may improve nerve function and prevent or reverse diabetic neuropathy in patients with type 1 diabetes.
Conclusion
C-peptide replacement therapy shows potential to improve nerve function in type 1 diabetes patients with early-stage neuropathy.
Supporting Evidence
- C-peptide replacement improved sensory nerve conduction velocity by 2.7 m/s in early-stage neuropathy patients.
- Patients receiving C-peptide showed a statistically significant greater improvement in nerve function compared to placebo.
- Improvements in heart rate variability were observed during C-peptide infusion, indicating better autonomic nerve function.
Takeaway
C-peptide is a substance that can help people with type 1 diabetes feel better by making their nerves work better.
Methodology
The study involved a double-blind, placebo-controlled trial with C-peptide replacement therapy over 6 months.
Potential Biases
Some patients had substantial nerve conduction deficits at baseline, which could affect results.
Limitations
The study duration was limited to 6 months, which may not capture long-term effects.
Participant Demographics
The average age of participants was 44 years, with an average diabetes duration of 29 years.
Statistical Information
P-Value
p < 0.032
Statistical Significance
p < 0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website